How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Following the transaction, Borgeson directly owns 6,429,863 shares of Recursion Pharmaceuticals. The company, while holding more cash than debt with a current ratio of 4.6, is quickly burning through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results